All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

A highly vascularized cancer that is especially reliant on tumor endothelial cells is clear cell renal cell carcinoma (ccRCC). Almost 80% of malignant tumors in the kidney are ccRCC ... She found that ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell RCC with or without ipilimumab.

Impact of renal cell cancer histology on outcomes of microscopic positive surgical margins and implications on post-surgical follow-up. Patients who received solid organ transplants at Mayo Clinic ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...

Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma ... patients with a normal contralateral kidney who have small ...

Dr. Xiaofan Lu presented the Abstract 442: Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191). Racial disparities ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...

Clear cell renal cell carcinoma (ccRCC ... antiprogrammed cell PD-1 IgG4k antibody that has been approved in China for the treatment of kidney carcinoma. The utilization of ICIs has shown significant ...

Objective: To characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC ... tissues derived from the ...